RU2010120845A - Фенилпирролидиновые соединения, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний - Google Patents

Фенилпирролидиновые соединения, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний Download PDF

Info

Publication number
RU2010120845A
RU2010120845A RU2010120845/04A RU2010120845A RU2010120845A RU 2010120845 A RU2010120845 A RU 2010120845A RU 2010120845/04 A RU2010120845/04 A RU 2010120845/04A RU 2010120845 A RU2010120845 A RU 2010120845A RU 2010120845 A RU2010120845 A RU 2010120845A
Authority
RU
Russia
Prior art keywords
pyrrolidin
methoxy
phenyl
diseases
melatonergic
Prior art date
Application number
RU2010120845/04A
Other languages
English (en)
Russian (ru)
Inventor
Антонио ГУЛЬЕТТА (IT)
Антонио ГУЛЬЕТТА
Альберт ПАЛОМЕР (ES)
Альберт Паломер
Хосе ФАЛЬКО (ES)
Хосе ФАЛЬКО
Original Assignee
Феррер Интернасионал, С.А. (Es)
Феррер Интернасионал, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Феррер Интернасионал, С.А. (Es), Феррер Интернасионал, С.А. filed Critical Феррер Интернасионал, С.А. (Es)
Publication of RU2010120845A publication Critical patent/RU2010120845A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2010120845/04A 2007-10-25 2008-10-23 Фенилпирролидиновые соединения, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний RU2010120845A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200702800 2007-10-25
ES200702800A ES2331276B1 (es) 2007-10-25 2007-10-25 Compuestos de fenilpirrolidina.

Publications (1)

Publication Number Publication Date
RU2010120845A true RU2010120845A (ru) 2011-11-27

Family

ID=40291255

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010120845/04A RU2010120845A (ru) 2007-10-25 2008-10-23 Фенилпирролидиновые соединения, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний

Country Status (21)

Country Link
US (1) US20120184594A1 (cg-RX-API-DMAC7.html)
EP (1) EP2203422B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011500764A (cg-RX-API-DMAC7.html)
KR (1) KR20100072287A (cg-RX-API-DMAC7.html)
CN (1) CN101878198A (cg-RX-API-DMAC7.html)
AR (1) AR069002A1 (cg-RX-API-DMAC7.html)
AT (1) ATE513809T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008316473A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0817660A2 (cg-RX-API-DMAC7.html)
CA (1) CA2703458A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008003141A1 (cg-RX-API-DMAC7.html)
DK (1) DK2203422T3 (cg-RX-API-DMAC7.html)
ES (2) ES2331276B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010004469A (cg-RX-API-DMAC7.html)
PL (1) PL2203422T3 (cg-RX-API-DMAC7.html)
PT (1) PT2203422E (cg-RX-API-DMAC7.html)
RU (1) RU2010120845A (cg-RX-API-DMAC7.html)
SI (1) SI2203422T1 (cg-RX-API-DMAC7.html)
TW (1) TW200920353A (cg-RX-API-DMAC7.html)
UY (1) UY31425A1 (cg-RX-API-DMAC7.html)
WO (1) WO2009053441A1 (cg-RX-API-DMAC7.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753709A (en) * 1995-06-07 1998-05-19 Bristol-Myers Squibb Company N-acyl-2 aryl cyclopropylmethylamine derivatives as melatonergics
PT1189900E (pt) * 1999-06-30 2004-05-31 Bristol Myers Squibb Co Derivados de aminopirrolidina heterociclicos utilizados como agentes melatonergicos

Also Published As

Publication number Publication date
BRPI0817660A2 (pt) 2015-09-29
PT2203422E (pt) 2011-09-26
AR069002A1 (es) 2009-12-23
TW200920353A (en) 2009-05-16
CN101878198A (zh) 2010-11-03
JP2011500764A (ja) 2011-01-06
UY31425A1 (es) 2009-04-30
CA2703458A1 (en) 2009-04-30
SI2203422T1 (sl) 2011-10-28
EP2203422B1 (en) 2011-06-22
PL2203422T3 (pl) 2011-11-30
AU2008316473A1 (en) 2009-04-30
DK2203422T3 (da) 2011-10-10
MX2010004469A (es) 2010-07-06
ES2331276A1 (es) 2009-12-28
ES2368697T3 (es) 2011-11-21
WO2009053441A1 (en) 2009-04-30
CL2008003141A1 (es) 2009-03-06
KR20100072287A (ko) 2010-06-30
US20120184594A1 (en) 2012-07-19
ATE513809T1 (de) 2011-07-15
ES2331276B1 (es) 2010-10-21
EP2203422A1 (en) 2010-07-07

Similar Documents

Publication Publication Date Title
KR20060040723A (ko) 우울증 치료용 로티고틴의 용도
JP2010504950A5 (cg-RX-API-DMAC7.html)
AU2011324414B2 (en) Trans-2-decenoic acid derivative and pharmaceutical agent containing the same
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ
JP2015521642A5 (cg-RX-API-DMAC7.html)
RU2015146305A (ru) Галактоолигосахаридная композиция и ее применение для предотвращения или лечения когнитивной дисфункции и эмоциональных расстройств при психоневрологических заболеваниях или старении
RU2005123808A (ru) Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств
CN1927193B (zh) 阿戈美拉汀在获得用于治疗抑郁患者睡眠障碍的药物中的用途
RU2010120847A (ru) Соединения индолина, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний
JP2011518859A5 (cg-RX-API-DMAC7.html)
RU2012101227A (ru) 1-(2-алкил-2,3-дигидро-бензофуран-4-ил)-пирролидин-3-иламинацильные соединения, фармацевтическая композиция и лекарственное средство на их основе и способ лечения или предупреждения мелатонергетических нарушений с их помощью
EP2127673A4 (en) PHARMACEUTICAL AGENT FOR THE PREVENTION AND TREATMENT OF SKIN DISORDERS BY ACCELERATED KERATINISATION
JP5634529B2 (ja) 強迫性障害(ocd)処置用の薬剤の製造のためのアゴメラチンの使用
WO2009127737A1 (en) Use of enantiomer (1s, 2r) of milnacipran hydrochloride for the preventive treatment of suicidal behaviour in depressed patients
AU2005314935A1 (en) Preventive or therapeutic agent for sleep disorder
KR20110011748A (ko) 각성을 향상시키는 방법
RU2010120846A (ru) Соединения 2,3-дигидробензофурана, фармацевтическая композиция на их основе и способ лечения или профилактики мелатонинергических заболеваний
UA121994C2 (uk) СЕЛЕКТИВНИЙ АМІД <font face="Symbol">g</font>-ГІДРОКСИМАСЛЯНОЇ КИСЛОТИ ТА ЙОГО ВИКОРИСТАННЯ ПРИ ЛІКУВАННІ ЗЛОВЖИВАННЯ АЛКОГОЛЕМ
HRP20090632T1 (hr) Novi derivati naftalena, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže
AR070003A1 (es) Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
Srinivasan et al. Sleep, mood disorders and antidepressants: the melatonergic antidepressant agomelatine offers a new strategy for treatment
WO2006105455A3 (en) Methods of treatment utilizing certain melatonin derivatives
CN109890798A (zh) 用于治疗cns病症的羟基去甲氯胺酮衍生物
AR070004A1 (es) Derivados naftalenicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
JP2012509860A5 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20121016